Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Elias Jabbour, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero, Guillermo Montalban Bravo, Koji Sasaki, Tapan M. Kadia, Joseph Khoury, Sa A. Wang, Fadi G. Haddad, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences